Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Nebulized Sodium Nitrite (AIR001) Following Repeat-Dose Inhalation in Healthy Subjects
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The efficacy of nebulized sodium nitrite (AIR001) has been demonstrated in animal models of pulmonary arterial hypertension (PAH), but it was not known if inhaled nitrite would be well tolerated in human subjects at exposure levels associated with efficacy in these models. METHODS: Inhaled nebulized sodium nitrite was assessed in three independent studies in a total of 82 healthy male and female subjects. Study objectives included determination of the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) under normal and mildly hypoxic conditions, and following co-administration with steady-state sildenafil, assessment of nitrite pharmacokinetics, and evaluation of the fraction exhaled nitric oxide (FENO) and concentrations of iron-nitrosyl hemoglobin (Hb(Fe)-NO) and S-nitrosothiols (R-SNO) as biomarkers of local and systemic NO exposure, respectively. RESULTS: Nebulized sodium nitrite was well tolerated following 6 days of every 8 h administration up to 90 mg, producing significant increases in circulating Hb(Fe)-NO, R-SNO, and FENO. Pulmonary absorption of nitrite was rapid and complete, and plasma exposure dose was proportional through the MTD dosage level of 90 mg, without accumulation following repeated inhalation. At higher dosage levels, DLTs were orthostasis (observed at 120 mg) and hypotension with tachycardia (at 176 mg), but venous methemoglobin did not exceed 3.0 % at any time in any subject. Neither the tolerability nor pharmacokinetics of nitrite was impacted by conditions of mild hypoxia, or co-administration with sildenafil, supporting the safe use of inhaled nitrite in the clinical setting of PAH. CONCLUSION: On the basis of these results, nebulized sodium nitrite (AIR001) has been advanced into randomized trials in PAH patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation
Cosby, K., Partovi, K. S., Crawford, J. H., Patel, R. P., Reiter, C. D., Martyr, S., Yang, B. K., Waclawiw, M. A., Zalos, G., Xu, X., et al. (2003) · Nature Medicine · doi:10.1038/nm954 · Cited by 1,807 · cited 15×
“An important nitrite reductase in blood is deoxyhemoglobin [5, 6], but many cellular”
BackgroundMethodInfluentialSelf-citationShiva, S., Huang, Z., Grubina, R., Sun, J., Ringwood, L. A., MacArthur, P. H., Xu, X., Murphy, E., Darley-Usmar, V. M., & Gladwin, M. T. (2007) · Circulation Research · doi:10.1161/01.res.0000260171.52224.6b · Cited by 599 · cited 1×
“enzymes can also catalyze this reduction under hypoxic conditions, such as myoglobin [7–9], xanthine oxidase [10– 12], aldehyde oxidase [13, 14], cytochrome c oxidase [15], and endothelial NO synthase [16, 17], all of which are expressed in human lung tissue and/or vascular smooth muscle [18–21].”
BackgroundSelf-citationCastello, P. R., David, P. S., McClure, T., Crook, Z., & Poyton, R. O. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.011 · Cited by 495
Gladwin, M. T., Shelhamer, J. H., Schechter, A. N., Pease-Fye, M. E., Waclawiw, M. A., Panza, J. A., Ognibene, F. P., & Cannon, R. O. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.21.11482 · Cited by 441
Self-citationHendgen-Cotta, U. B., Merx, M. W., Shiva, S., Schmitz, J., Becher, S., Klare, J. P., Steinhoff, H.-J., Goedecke, A., Schrader, J., Gladwin, M. T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801336105 · Cited by 418 · cited 1×
“enzymes can also catalyze this reduction under hypoxic conditions, such as myoglobin [7–9], xanthine oxidase [10– 12], aldehyde oxidase [13, 14], cytochrome c oxidase [15], and endothelial NO synthase [16, 17], all of which are expressed in human lung tissue and/or vascular smooth muscle [18–21].”
BackgroundSelf-citationReduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase
Godber, B. L. J., Doel, J. J., Sapkota, G. P., Blake, D. R., Stevens, C. R., Eisenthal, R., & Harrison, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.7757 · Cited by 411
Erythrocytes are the major intravascular storage sites of nitrite in human blood
Dejam, A. (2005) · Blood · doi:10.1182/blood-2005-02-0567 · Cited by 350 · cited 1×
“5 reported for nitrite [39], the resulting CL/F value of 1.”
BackgroundDejam, A., Hunter, C. J., Tremonti, C., Pluta, R. M., Hon, Y. Y., Grimes, G., Partovi, K., Pelletier, M. M., Oldfield, E. H., Cannon, R. O., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.712133 · Cited by 334
Self-citationCannon, R. O., Schechter, A. N., Panza, J. A., Ognibene, F. P., Pease-Fye, M. E., Waclawiw, M. A., Shelhamer, J. H., & Gladwin, M. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112761 · Cited by 298
Self-citationRassaf, T., Flögel, U., Drexhage, C., Hendgen-Cotta, U., Kelm, M., & Schrader, J. (2007) · Circulation Research · doi:10.1161/circresaha.107.152488 · Cited by 284 · cited 1×
“enzymes can also catalyze this reduction under hypoxic conditions, such as myoglobin [7–9], xanthine oxidase [10– 12], aldehyde oxidase [13, 14], cytochrome c oxidase [15], and endothelial NO synthase [16, 17], all of which are expressed in human lung tissue and/or vascular smooth muscle [18–21].”
BackgroundInhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator
Hunter, C. J., Dejam, A., Blood, A. B., Shields, H., Kim-Shapiro, D. B., Machado, R. F., Tarekegn, S., Mulla, N., Hopper, A. O., Schechter, A. N., et al. (2004) · Nature Medicine · doi:10.1038/nm1109 · Cited by 281 · cited 2×
“In an ovine model of pulmonary hypertension induced by hypoxia, pulmonary artery pressure (PAP) was significantly reduced by inhalation of both NO gas and nebulized sodium nitrite, but the effects of NO gas disappeared immediately after cessation of exposure, while decreases in PAP following inhalation of nitrite were…”
BackgroundInfluentialSelf-citationCharacterization of the Magnitude and Kinetics of Xanthine Oxidase-catalyzed Nitrite Reduction
Li, H., Samouilov, A., Liu, X., & Zweier, J. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011648200 · Cited by 280
Hypoxic Modulation of Exogenous Nitrite-Induced Vasodilation in Humans
Maher, A. R., Milsom, A. B., Gunaruwan, P., Abozguia, K., Ahmed, I., Weaver, R. A., Thomas, P., Ashrafian, H., Born, G. V. R., James, P. E., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.719591 · Cited by 210
Zuckerbraun, B. S., Shiva, S., Ifedigbo, E., Mathier, M. A., Mollen, K. P., Rao, J., Bauer, P. M., Choi, J. J. W., Curtis, E., Choi, A. M. K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.891077 · Cited by 192 · cited 18×
“Untreated PAH is associated with vascular proliferation and remodeling, hypertrophy, and eventual failure of the right ventricle and a median untreated life expectancy of less than 3 years.”
BackgroundInfluentialSelf-citationNitric oxide synthase reduces nitrite to NO under anoxia
Vanin, A. F., Bevers, L. M., Slama-Schwok, A., & van Faassen, E. E. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6374-2 · Cited by 151 · cited 1×
“enzymes can also catalyze this reduction under hypoxic conditions, such as myoglobin [7–9], xanthine oxidase [10– 12], aldehyde oxidase [13, 14], cytochrome c oxidase [15], and endothelial NO synthase [16, 17], all of which are expressed in human lung tissue and/or vascular smooth muscle [18–21].”
BackgroundEndothelial nitric oxide synthase reduces nitrite anions to NO under anoxia
Gautier, C., van Faassen, E., Mikula, I., Martasek, P., & Slama-Schwok, A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.031 · Cited by 143 · cited 1×
“enzymes can also catalyze this reduction under hypoxic conditions, such as myoglobin [7–9], xanthine oxidase [10– 12], aldehyde oxidase [13, 14], cytochrome c oxidase [15], and endothelial NO synthase [16, 17], all of which are expressed in human lung tissue and/or vascular smooth muscle [18–21].”
BackgroundLi, H., Kundu, T. K., & Zweier, J. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.019125 · Cited by 126 · cited 1×
“enzymes can also catalyze this reduction under hypoxic conditions, such as myoglobin [7–9], xanthine oxidase [10– 12], aldehyde oxidase [13, 14], cytochrome c oxidase [15], and endothelial NO synthase [16, 17], all of which are expressed in human lung tissue and/or vascular smooth muscle [18–21].”
BackgroundSafety and Feasibility of Long-term Intravenous Sodium Nitrite Infusion in Healthy Volunteers
Pluta, R. M., Oldfield, E. H., Bakhtian, K. D., Fathi, A. R., Smith, R. K., DeVroom, H. L., Nahavandi, M., Woo, S., Figg, W. D., & Lonser, R. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014504 · Cited by 112 · cited 2×
“8 h [25]) administration of nitrite in healthy subjects.”
BackgroundMethodEffective Half‐Life in Clinical Pharmacology
Boxenbaum, H., & Battle, M. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04117.x · Cited by 106 · cited 1×
“, one dosing interval), but steady-state accumulation of 50 % following every 8 h dosing is consistent with an effective t1/2 of approximately 5 h [37].”
BackgroundBioavailability of sodium nitrite from an aqueous solution in healthy adults
Hunault, C. C., van Velzen, A. G., Sips, A. J. A. M., Schothorst, R. C., & Meulenbelt, J. (2009) · Toxicology Letters · doi:10.1016/j.toxlet.2009.06.865 · Cited by 102 · cited 3×
“The effective t1/2 of 5 h estimated for the nitrate metabolite is in good agreement with that reported for nitrate following intra-arterial nitrite infusion (6 h [24]), intravenous nitrite infusion (8 h [29]), or following oral administration of nitrate itself (5 h [41]).”
MethodResultIngram, T. E., Pinder, A. G., Bailey, D. M., Fraser, A. G., & James, P. E. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00583.2009 · Cited by 78
Bueno, M., Wang, J., Mora, A. L., & Gladwin, M. T. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4833 · Cited by 68
Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study
Mack, A. K., McGowan II, V. R., Tremonti, C. K., Ackah, D., Barnett, C., Machado, R. F., Gladwin, M. T., & Kato, G. J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07259.x · Cited by 64 · cited 1×
“Nitrite has been extensively studied in human subjects following parenteral administration, and a number of published studies have assessed the pharmacokinetics and pharmacodynamics of sodium nitrite in humans following intravenous [25, 28–30] or intra-arterial [6, 24, 26, 31, 32] administration.”
BackgroundInfluentialSelf-citationOxygen Regulates Tissue Nitrite Metabolism
Curtis, E., Hsu, L. L., Noguchi, A. C., Geary, L., & Shiva, S. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4242 · Cited by 46 · cited 12×
“The levels of R-SNO measured in plasma were 10-fold lower than those in whole blood, suggesting that the major S-nitrosylated blood protein is erythrocytic hemoglobin, while our methods cannot differentiate the specific S-nitrosothiols represented by the smaller plasma fraction (e.g., S-nitrosylated albumin, nitrosogl…”
BackgroundInfluentialSelf-citationMaher, A. R., Arif, S., Madhani, M., Abozguia, K., Ahmed, I., Fernandez, B. O., Feelisch, M., O'Sullivan, A., Christopoulos, A., Sverdlov, A. L., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12152 · Cited by 26 · cited 1×
“Nitrite has been extensively studied in human subjects following parenteral administration, and a number of published studies have assessed the pharmacokinetics and pharmacodynamics of sodium nitrite in humans following intravenous [25, 28–30] or intra-arterial [6, 24, 26, 31, 32] administration.”
BackgroundInfluential
Cited by
Strategies to increase nitric oxide signalling in cardiovascular disease
Lundberg, J. O., Gladwin, M. T., & Weitzberg, E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4623 · Cited by 576
Self-citationLai, Y.-C., Tabima, D. M., Dube, J. J., Hughan, K. S., Vanderpool, R. R., Goncharov, D. A., St. Croix, C. M., Garcia-Ocaña, A., Goncharova, E. A., Tofovic, S. P., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.018935 · Cited by 270
“Recent publications from our group and others have shown that nitrite exhibits therapeutic efficacy in mouse, rat, and sheep preclinical models of PH and also appears to be well tolerated in humans.(18) In addition, oral supplementation of nitrate prevents the development of hypoxia- and monocrotaline-induced PH.”
BackgroundKapil, V., Khambata, R. S., Jones, D. A., Rathod, K., Primus, C., Massimo, G., Fukuto, J. M., & Ahluwalia, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019240 · Cited by 248
Borlaug, B. A., Koepp, K. E., & Melenovsky, V. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.067 · Cited by 223
“Plasma nitrite concentrations were assessed in the final 6 subjects enrolled in the trial using a liquid chromatography– fluorometric assay (BASi, West Lafayette, Indiana) as previously described (20).”
BackgroundMethodInfluentialTherapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases
Omar, S. A., Webb, A. J., Lundberg, J. O., & Weitzberg, E. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12441 · Cited by 175
Metadata
- Authors
- Rix, P. J., Vick, A., Attkins, N. J., Barker, G. E., Bott, A. W., Alcorn, H., Gladwin, M. T., Shiva, S., Bradley, S., Hussaini, A., Hoye, W. L., Parsley, E. L., & Masamune, H.
- Venue
- Clinical Pharmacokinetics
- Published
- 2014-11-25
- Volume
- 54
- Issue
- 3
- Pages
- 261-272
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W1999575173
- Cited by
- 48
- References
- 25
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.